Finally, future clinical trials of TLR7 neutralizing antibodies, and inhibitors of human tryptase-β should be undertaken in patients with COPD to determine the clinical benefit and their potential as therapeutics. Here, TLR7 is linked to chronic obstructive pulmonary disease.